文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病t(8;16)(p11;p13)患者的特征与结局:国际协作研究

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
PubMed 文献 · Br J Haematol · 2021-02-02

该国际协作研究纳入59例伴t(8;16)(p11;p13)/MYST3-CREBBP的AML患者,中位年龄52岁,58%为原发AML,37%为治疗相关AML,5%为继发于MDS的AML。异基因造血干细胞移植在首次完全缓解时显著改善生存,尤其在原发AML患者中。

要点

  • t(8;16) AML罕见,强化化疗后5年生存率仅17%。
  • 继发/治疗相关AML和复杂核型患者预后更差。
  • 首次完全缓解期行异基因移植可显著改善生存。

核心结论

  • t(8;16) AML化疗结局差,5年生存率17%,首次完全缓解期异基因移植可能显著改善生存。

研究设计与样本

  • 国际协作研究纳入59例伴t(8;16)(p11;p13)的AML患者,中位年龄52岁(范围16-75岁)。
  • 对10例患者子集进行全基因组测序。

主要发现

  • AML为原发者占58%,治疗相关者占37%,继发于MDS者占5%。
  • 细胞遗传学显示复杂核型占43%。

关键数值与推荐

  • 全基因组测序(10例)检出ASXL1、BRD3、FLT3、MLH1、POLG、TP53、SAMD4B突变各3例,EYS、KRTAP9-1、SPTBN5突变各4例,RUNX1和TET2突变各2例。
  • 多因素分析显示首次完全缓解期异基因移植在原发AML中有效,但在继发/治疗相关AML中无效,在复杂核型患者中效果较差。

临床怎么用

  • 对t(8;16) AML患者,应考虑在首次完全缓解期进行异基因造血干细胞移植以改善生存。
  • 继发/治疗相关AML或复杂核型患者预后尤其差,需谨慎评估移植获益。

局限性

  • 样本量小(59例),全基因组测序仅10例。
  • 回顾性研究设计可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5·48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0·01) and those with complex karyotype (P = 0·04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0·04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kayser S, Hills RK, Langova R, et al. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. Br J Haematol. 2021. PMID: 33529373. doi:10.1111/bjh.17336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。